ea0096p7 | Section | UKINETS2023
Irene Wotherspoon Sister
, Martin Dr. Amy
, McIntosh Dr. DAvid
, Reed Prof Nick
Approximately 230 new patients with GEP-NEN are referred annually to the centre. Prevalence of GEP-NEN is increasing due to the availability of 2nd, 3rd or 4th line treatments. Oral chemotherapy is being used with increasing frequency in this setting. The NEN Team wished to explore the outcomes of patients treated with temozolomide singe agent and temozolomide/capecitabine during the previous 5 years and compare the findings with current literature. 18 patients were included i...